Interview with Ala Ciobanu, General Manager, Roche Ukraine
As a leader responsible for heading Roche’s operations since its establishment of an LLC in Ukraine in 2009, what do you consider have been the main achievements of the company?…
Address: Roche Products Ltd, Hexagon Place, 6 Falcon Way, Welwyn Garden City, Hertfordshire, AL7 1TW, United Kingdom
Tel: +44 (0)1707 366000
Web: http://www.roche.co.uk/portal/uk
Headquartered in Basel, Switzerland, Roche employs around 2,000 people in the UK in pharmaceuticals, based at Welwyn Garden City in Hertfordshire, and diagnostics, based at Burgess Hill in East Sussex.
The UK pharmaceuticals headquarters at Welwyn Garden City in Hertfordshire is home to Roche’ global pharmaceutical product development team, its pharmaceuticals sales and marketing teams and corporate functions.
The purpose built facility that opened in 2005 at Shire Park in Welwyn Garden City, reflects and supports the continued success of Roche’s pharmaceutical business.
In 2006 Roche’ UK diagnostics sales and marketing team relocated to a new purpose-built facility in Burgess Hill, East Sussex.
As the UK’s leading in-vitro diagnostics company, Roche has a dynamic UK sales and marketing team who consistently deliver growth above the market rate.
As one of the major pharmaceutical and diagnostic companies in the UK, Roche develops and provides an innovative range of products and services that help healthcare professionals improve the health and well-being of the UK population.
As a leader responsible for heading Roche’s operations since its establishment of an LLC in Ukraine in 2009, what do you consider have been the main achievements of the company?…
Britain, home of the discovery of the world’s first ever vaccine, has long been championing a pharma sub-segment forecast to reach a global market value of USD 49.27 billion by…
Thomas Bo Bjorn Klee, managing director of Lundbeck UK and Ireland, describes the global restructuring program Lundbeck initiated two years ago to ensure value creation, build on unique strengths and…
Having recently been able to present positive data for their lead technology IMCgp100 in uveal melanoma at the American Society of Clinical Oncology (ASCO), Immunocore looks at its future as…
Erik Nordkamp, managing director of Pfizer UK shares his thoughts on the future of healthcare and the role that Pfizer and the UK can play in shaping it. He explains…
Stewart Pearce, managing director of Otsuka UK and Ireland since 2017 discloses how he built up a leadership team fit for the Otsuka of 2023 and highlights what he appreciates…
As the UK extracts itself from the European Union, key figures from the country’s life sciences sector are split on the implications of Brexit for their industry. “The UK pharmaceutical…
Chris Molloy, chief executive of the Medicines Discovery Catapult (MDC), discusses its role within the UK as a center for applied medical R&D and the future of the country’s drug…
Confirming Eisai’s commitment to keeping its EMEA headquarters in the UK, Gary Hendler, chairman and CEO EMEA, and Nick Burgin, COO and president of global value and access stress how…
Only 14 months in position, UK country president at Novartis, Haseeb Ahmad, shares insights into the company’s new strategy. He further analyses how Brexit can be a catalysing force for…
Recently appointed CEO of Health Innovation Manchester, Ben Bridgewater explains the organization’s goal of improving the lives of the people of Greater Manchester by ensuring a constant pipeline of innovation,…
Taking the conversation beyond Brexit, His Excellency Lars Thuesen, ambassador of Denmark to the UK, highlights the solid ties that have linked both countries since the Danes invaded the island…
The Ambassador of Switzerland to the UK, Alexandre Fasel, discloses what has been achieved so far with the ‘Mind the Gap’ strategy, aimed at safeguarding British-Swiss economic and business…
See our Cookie Privacy Policy Here
